Comments
Loading...

Vertex Pharmaceuticals アナリスト評価

VRTXNASDAQ
ロゴは Benzinga Data から提供されました
公共との取引
公共との取引
$409.47
-6.78-1.63%
近くで: -
$410.50
1.030.25%
時間外: 7:52 PM EDT
Q3 2025に発表されました。期中 {{formatedDate}}に決算が発表されました{{formatedDate}} マーケットクローズ後。
直近の電話会議は16:30 PM, 5 days agoに開始しました。クリックしてウェブキャストを見る
コンセンサス評価1
Buy
最高目標株価1
$575.00
最低目標株価1
$411.00
コンセンサス目標株価1
$489.17

アナリストの評価、目標株価、予想

Vertex Pharmaceuticals Inc のコンセンサス目標株価は $489.17 で、26 人のアナリストの評価に基づいています。最高値は $57510 2, 2025Citigroup が発表)、最安値は $4118 6, 2025Canaccord Genuity が発表)です。直近のアナリスト評価 3 件は UBS、RBC Capital、Barclays により 11 7, 2025、11 4, 2025、11 4, 2025 に発表されました。UBS、RBC Capital、Barclays の平均目標株価は $458.33 で、これらの最新評価から Vertex Pharmaceuticals Inc に対して 11.65% のupsideが示唆されています。

推奨アナリスト会社1

UBS
RBC Capital
Barclays
Stifel
Morgan Stanley

1アナリスト評価から算出

Vertex Pharmaceuticalsのアナリスト評価

Buy Now
Get Alert
11/07/2025
33.01%
UBS
$553 → $546
Maintains
Buy
11/04/2025
1.1%
RBC Capital
$423 → $415
Maintains
Sector Perform
11/04/2025
0.85%
Barclays
$408 → $414
Maintains
Equal-Weight
11/04/2025
8.4%
Stifel
$455 → $445
Maintains
Hold
10/10/2025
6.7%
Morgan Stanley
$439 → $438
Maintains
Equal-Weight
10/08/2025
29.11%
JP Morgan
$517 → $530
Maintains
Overweight
10/02/2025
40.07%
Citigroup
$550 → $575
Maintains
Buy
09/25/2025
11.08%
Leerink Partners
$458 → $456
Upgrade
Market Perform → Outperform
09/11/2025
15.71%
Evercore ISI Group
$510 → $475
Maintains
Outperform
09/03/2025
Raymond James
Initiates
→ Market Perform
08/07/2025
33.98%
Citigroup
$575 → $550
Maintains
Buy
08/06/2025
0.12%
Canaccord Genuity
$424 → $411
Maintains
Hold
08/06/2025
33.01%
Guggenheim
$558 → $546
Maintains
Buy
08/06/2025
12.06%
Wells Fargo
$460 → $460
Upgrade
Equal-Weight → Overweight
08/05/2025
19.37%
Truist Securities
$520 → $490
Maintains
Buy
08/05/2025
6.7%
Scotiabank
$442 → $438
Maintains
Sector Perform
08/05/2025
29.11%
BMO Capital
$557 → $530
Maintains
Outperform
08/05/2025
-1.34%
RBC Capital
$430 → $405
Maintains
Sector Perform
08/05/2025
34.71%
UBS
$582 → $553
Maintains
Buy
08/05/2025
10.84%
Stifel
$494 → $455
Maintains
Hold
08/05/2025
18.15%
Cantor Fitzgerald
$535 → $485
Maintains
Overweight
08/05/2025
6.94%
Morgan Stanley
$460 → $439
Maintains
Equal-Weight
08/05/2025
16.44%
HC Wainwright & Co.
$550 → $478
Maintains
Buy
07/14/2025
25.94%
JP Morgan
$515 → $517
Maintains
Overweight
06/23/2025
33.98%
HC Wainwright & Co.
$550 → $550
Reiterates
Buy → Buy
06/20/2025
12.06%
Morgan Stanley
$464 → $460
Maintains
Equal-Weight
06/17/2025
2.31%
RBC Capital
$423 → $420
Maintains
Sector Perform
05/06/2025
3.05%
RBC Capital
$420 → $423
Maintains
Sector Perform
05/06/2025
7.67%
Scotiabank
$450 → $442
Maintains
Sector Perform
05/06/2025
13.03%
Morgan Stanley
$462 → $464
Maintains
Equal-Weight
05/06/2025
25.46%
JP Morgan
$512 → $515
Maintains
Overweight
05/06/2025
30.33%
Cantor Fitzgerald
$535 → $535
Reiterates
Overweight → Overweight
05/06/2025
Needham
Reiterates
Hold → Hold
05/06/2025
22.53%
Leerink Partners
$550 → $503
Downgrade
Outperform → Market Perform
04/22/2025
30.33%
Cantor Fitzgerald
→ $535
Assumes
→ Overweight
04/01/2025
2.31%
RBC Capital
$408 → $420
Maintains
Sector Perform
03/31/2025
38.12%
B of A Securities
$555 → $567
Maintains
Buy
02/20/2025
-0.61%
RBC Capital
$407 → $408
Maintains
Sector Perform
02/12/2025
3.29%
Canaccord Genuity
$408 → $424
Upgrade
Sell → Hold
02/11/2025
42.02%
UBS
$586 → $583
Maintains
Buy
02/11/2025
35.2%
B of A Securities
$540 → $555
Maintains
Buy
02/11/2025
26.67%
Truist Securities
$460 → $520
Maintains
Buy
02/11/2025
-0.85%
RBC Capital
$402 → $407
Maintains
Sector Perform
02/11/2025
9.62%
Scotiabank
$433 → $450
Maintains
Sector Perform
02/11/2025
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight
02/11/2025
13.76%
Barclays
$435 → $467
Maintains
Equal-Weight
02/11/2025
33.98%
HC Wainwright & Co.
$550 → $550
Reiterates
Buy → Buy
02/11/2025
11.81%
Morgan Stanley
$450 → $459
Maintains
Equal-Weight
02/11/2025
Needham
Reiterates
Hold → Hold
02/04/2025
31.55%
B of A Securities
$522 → $540
Maintains
Buy
01/31/2025
5.97%
Barclays
$418 → $435
Maintains
Equal-Weight
01/31/2025
32.76%
BMO Capital
$520 → $545
Maintains
Outperform
01/31/2025
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight
01/31/2025
5.48%
Scotiabank
$430 → $433
Maintains
Sector Perform
01/31/2025
33.98%
HC Wainwright & Co.
$535 → $550
Maintains
Buy
01/31/2025
Needham
Reiterates
Hold → Hold
01/30/2025
12.06%
Wells Fargo
$460 → $460
Downgrade
Overweight → Equal-Weight
01/27/2025
29.84%
Piper Sandler
$535 → $533
Maintains
Overweight
01/24/2025
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight
01/10/2025
11.08%
Morgan Stanley
$476 → $456
Maintains
Equal-Weight
01/10/2025
12.06%
Wells Fargo
$555 → $460
Maintains
Overweight
12/23/2024
12.06%
Truist Securities
$550 → $460
Maintains
Buy
12/23/2024
4.75%
Scotiabank
$426 → $430
Maintains
Sector Perform
12/23/2024
21.8%
JP Morgan
$503 → $500
Maintains
Overweight
12/20/2024
-2.56%
RBC Capital
$451 → $400
Maintains
Sector Perform
12/20/2024
1.83%
Barclays
$509 → $418
Maintains
Equal-Weight
12/20/2024
26.67%
BMO Capital
$566 → $520
Maintains
Outperform
12/20/2024
Needham
Reiterates
Hold → Hold
12/20/2024
30.33%
HC Wainwright & Co.
$600 → $535
Maintains
Buy
12/19/2024
Oppenheimer
Downgrade
Outperform → Perform
12/19/2024
27.16%
B of A Securities
$545 → $522
Maintains
Buy
12/16/2024
20.34%
Stifel
$490 → $494
Maintains
Hold
12/09/2024
33.98%
Jefferies
$500 → $550
Upgrade
Hold → Buy
11/14/2024
40.07%
Citigroup
→ $575
Initiates
→ Buy
11/06/2024
-0.61%
Canaccord Genuity
$361 → $408
Maintains
Sell
11/05/2024
18.39%
Scotiabank
$480 → $486
Maintains
Sector Perform
11/05/2024
42.75%
UBS
$562 → $586
Maintains
Buy
11/05/2024
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight
11/05/2024
9.87%
RBC Capital
$437 → $451
Maintains
Sector Perform
11/05/2024
22.53%
JP Morgan
$510 → $503
Maintains
Overweight
11/05/2024
15.96%
Morgan Stanley
$473 → $476
Maintains
Equal-Weight
10/30/2024
31.55%
Oppenheimer
$550 → $540
Maintains
Outperform
10/21/2024
46.16%
HC Wainwright & Co.
$600 → $600
Reiterates
Buy → Buy
10/17/2024
36.91%
UBS
$477 → $562
Maintains
Buy
10/16/2024
16.93%
Scotiabank
→ $480
Initiates
→ Sector Perform
10/14/2024
31.79%
B of A Securities
$550 → $541
Maintains
Buy
10/10/2024
Raymond James
Reinstates
→ Market Perform
10/09/2024
6.46%
RBC Capital
$425 → $437
Maintains
Sector Perform
10/08/2024
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight
10/04/2024
3.53%
RBC Capital
$431 → $425
Maintains
Sector Perform
10/01/2024
15.47%
Morgan Stanley
$462 → $474
Maintains
Equal-Weight
09/19/2024
4.99%
RBC Capital
$431 → $431
Reiterates
Sector Perform → Sector Perform
08/05/2024
46.16%
HC Wainwright & Co.
$500 → $600
Maintains
Buy
08/05/2024
33.98%
Oppenheimer
$500 → $550
Maintains
Outperform
08/05/2024
24.24%
JP Morgan
$505 → $510
Maintains
Overweight
08/05/2024
33.98%
Truist Securities
$508 → $550
Reiterates
Buy → Buy
08/05/2024
24%
Barclays
$472 → $509
Downgrade
Overweight → Equal-Weight
08/02/2024
25.46%
Evercore ISI Group
$438 → $515
Maintains
Outperform
08/02/2024
35.93%
Guggenheim
$450 → $558
Maintains
Buy
08/02/2024
16.93%
Cantor Fitzgerald
$480 → $480
Reiterates
Overweight → Overweight

よくある質問

Q

Vertex Pharmaceuticals (VRTX) 株の目標株価はいくらですか?

A

Vertex Pharmaceuticalsの最新目標株価Vertex Pharmaceuticals。(NASDAQ:VRTX) の最新目標株価をUBSが11 7, 2025日に発表した。このアナリスト会社はVertex Pharmaceuticals ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内(33.01% upsideの可能性あり)と予想する$546.00の目標株価を設定しました。過去1年間に74のアナリスト会社がレーティングを報告しています。

Q

Vertex Pharmaceuticals (Vertex Pharmaceuticalsの直近のアナリスト評価は?(VRTX) の直近のアナリスト評価は?

A

Vertex Pharmaceuticalsの最新のアナリストレーティングはVertex Pharmaceuticalsです。(NASDAQ:VRTX) の最新のアナリストレーティングはUBSによるもので、Vertex PharmaceuticalsのVertex Pharmaceuticalsです。{actionCompany}}のbuy評価です。

Q

Vertex Pharmaceuticals (VRTXの直近のアップグレードはいつですか?(VRTX) の最後のアップグレードはいつですか?

A

Vertex Pharmaceuticals Incの最後のアップグレードは9 25, 2025日に行われ、Leerink Partnersは目標株価を$456に引き上げました。companyName}}のLeerink Partnersの以前のa market performは$456でした。

Q

Vertex Pharmaceuticals (Vertex Pharmaceuticalsの直近の格下げ日はいつですか?(VRTX) の最後の格下げはいつですか?

A

Vertex Pharmaceuticals Incの最後の格下げは5 6, 2025日にLeerink PartnersがVertex Pharmaceuticals Incの目標株価を$550から$503に変更した時です。

Q

Vertex Pharmaceuticals (Vertex Pharmaceuticalsの次のアナリストレーティングはいつ発表・更新されますか?(VRTX) の次の格付けはいつですか?

A

アナリストは、公開財務諸表を調べたり、Vertex Pharmaceuticalsの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは11 7, 2025日に提出されましたので、次のレーティングは11 7, 2026日あたりに提出されるものと思われます。

Q

Vertex PharmaceuticalsのアナリストレーティングはVertex Pharmaceuticalsですか?(VRTX) は正しいですか?

A

レーティングは主観的なものであり変化しますが、最新のVertex Pharmaceuticals (VRTX) (VRTX) のレーティングは維持で、目標株価は$553.00から$546.00でした。現在の価格 Vertex Pharmaceuticals ({{exchange}}) (VRTX) の現在の取引価格は$410.50で、これはアナリストの予測レンジout ofです。

ブラウズ アナリスト評価と目標株価 全銘柄の

こんな人も見ています